Buscar

Barra de búsqueda
01/01/2023 Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (Nature Communications, (2023), 14, 1, (1070), 10.1038/s41467-023-35961-y)
Chmielecki J., Gray J.E., Cheng Y., Ohe Y., Imamura F., Cho B.C., Lin M.-C., Majem M., Shah R., Rukazenkov Y., Todd A., Markovets A., Barrett J.C., Hartmaier R.J., Ramalingam S.S.. Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (Nature Communications, (2023), 14, 1, (1070), 10.1038/s41467-023-35961-y). Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-38999-0. PMID:37263992. IF:14.700(Q1/1D).
01/01/2023 BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors
Bertran-Alamillo J., Giménez-Capitán A., Román R., Talbot S., Whiteley R., Floc’h N., Martínez-Pérez E., Martin M.J., Smith P.D., Sullivan I., Terp M.G., Saeh J., Marino-Buslje C., Fabbri G., Guo G., Xu M., Tornador C., Aguilar-Hernández A., Reguart N., Ditzel H.J., Martínez-Bueno A., Nabau-Moretó N., Gascó A., Rosell R., Pease J.E., Polanska U.M., Travers J., Urosevic J., Molina-Vila M.A.. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors. Molecular Cancer. 2023; 22(1)DOI:10.1186/s12943-023-01815-w. PMID:37443114. IF:27.700(Q1/1D).
01/01/2023 Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)
Karachaliou N., Codony-Servat J., Teixidó C., Pilotto S., Drozdowskyj A., Codony-Servat C., Giménez-Capitán A., Molina-Vila M.A., Bertrán-Alamillo J., Gervais R., Massuti B., Morán T., Majem M., Felip E., Carcereny E., García-Campelo R., Viteri S., González-Cao M., Morales-Espinosa D., Verlicchi A., Crisetti E., Chaib I., Santarpia M., Luis Ramírez J., Bosch-Barrera J., Felipe Cardona A., de Marinis F., López-Vivanco G., Miguel Sánchez J., Vergnenegre A., Sánchez Hernández J.J., Sperduti I., Bria E., Rosell R.. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499). Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-30374-9. PMID:36869103. IF:3.800(Q1/2D).
01/01/2023 Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain
De Castro J., Insa A., Collado-Borrell R., Escudero-Vilaplana V., Martínez A., Fernandez E., Sullivan I., Arrabal N., Carcedo D., Manzaneque A.. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulmonary Medicine. 2023; 23(1)DOI:10.1186/s12890-023-02356-0. PMID:36809990. IF:2.600(Q2/5D).
01/01/2023 Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study
Manzano J.L., Martin-Liberal J., Fernández-Morales L.A., Benítez G., Medina Martínez J., Quindós M., García-Castaño A., Fernández O., Simo R.V., Majem M., Bellido L., Ayala de Miguel P., Campos B., Espinosa E., Macías Cerrolaza J.A., Gil-Arnaiz I., Lorente D., Rodriguez-Lescure A., Perez V.N., López Castro R., Gramaje M.G., Puértolas T., Rodriguez Moreno J.F., Espasa Font L., Belaustegui Ferrández G., Cerezuela-Fuentes P.. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study. MELANOMA RESEARCH. 2023; 33(5)DOI:10.1097/CMR.0000000000000888. PMID:36988401. IF:1.500(Q3/7D).
01/01/2023 Immunogenicity of COVID-19 vaccines in lung cancer patients
Provencio M., Estival A., Franco F., López-Vivanco G., Saigí M., Arasanz H., Diz P., Carcereny E., García J., Aguado C., Mosquera J., Iruarrizaga E., Majem M., Bosch-Barrera J., Mielgo-Rubio X., Guirado M., Juan-Vidal Ó., Blasco A., Lucía Gozálvez C., Del Barrio A., De Portugal T., López-Martín A., Serrano G., Campos B., Rubio J., Catot S., Esteban B., Martí-Ciriquian J.L., del Barco E., Calvo V.. Immunogenicity of COVID-19 vaccines in lung cancer patients. LUNG CANCER. 2023; 184DOI:10.1016/j.lungcan.2023.107323. PMID:37639820. IF:4.500(Q1/2D).
01/01/2023 Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
O'Donnell P.H., Milowsky M.I., Petrylak D.P., Hoimes C.J., Flaig T.W., Mar N., Moon H.H., Friedlander T.W., McKay R.R., Bilen M.A., Srinivas S., Burgess E.F., Ramamurthy C., George S., Geynisman D.M., Bracarda S., Borchiellini D., Geoffrois L., Maroto Rey J.P., Ferrario C., Carret A.-S., Yu Y., Guseva M., Homet Moreno B., Rosenberg J.E.. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(25)DOI:10.1200/JCO.22.02887. PMID:37369081. IF:42.100(Q1/1D).
01/01/2023 Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes
Blanco R., Dómine M., González J.L., Loutfi S., Alfaro J., Saldaña J., Rubio J., Campos B., Hidalgo J., Barba A., Márquez D., Martin M., Olaverri A., Nadal E.. Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. LUNG CANCER. 2023; 183DOI:10.1016/j.lungcan.2023.107318. PMID:37557022. IF:4.500(Q1/2D).